title: HER2 status in breast cancer: experience of a Spanish National Reference Centre.
abstract: BACKGROUND
  Accurate HER2 testing is of great clinical value for the identification of breast cancer patients who are eligible for trastuzumab therapy. The aim of this study is to review breast carcinomas diagnosed from 2001 to 2007 at a Spanish National Reference Centre for HER2 testing, evaluating the agreement between HER2 immunohistochemical (IHC) tests and fluorescence in situ hybridisation (FISH) tests.
  
  
  METHODS
  Demographic and clinical information was obtained from 2751 breast carcinoma patients. HER2 IHC and FISH tests were performed both in a local laboratory and in the reference centre. The HER2 IHC0/1+, IHC2+, IHC3+ and FISH-positive patients comprised 64%, 20%, 16% and 24% of the available population, respectively (results from the reference centre). Using statistical approaches, we evaluated the agreement between: (1) HER2 IHC and FISH tests, and (2) results provided by the local and the reference laboratories.
  
  
  RESULTS
  The data confirmed a statistically significant relation between HER2 overexpression and amplification. We also found that instances of polysomy 17 and heterogeneous patterns of HER2 expression (heterogeneous staining distribution in different areas of the same tumour) are more frequently observed in HER2-positive tumours. Finally, since the diagnoses were made from 2001 to 2007, we could also observe a rising agreement rate between laboratories/pathologists with time.
  
  
  CONCLUSIONS
  HER2 testing is most accurate when performed by experienced pathologists and at a high-volume reference laboratory. Polysomy 17 and HER2 heterogeneous staining patterns should also be considered for a better understanding of the variation in the anti-HER2 therapeutic response.
authors: Department of Computer Science and Artificial Intelligence, University of Granada, Granada, Spain. marta@decsai.ugr.es
authors: Marta
authors: M
authors: Cuadros
authors: Carlos
authors: C
authors: Cano
authors: Francisco Javier
authors: FJ
authors: López
authors: Paloma
authors: P
authors: Talavera
authors: Inmaculada
authors: I
authors: García-Peréz
authors: Armando
authors: A
authors: Blanco
authors: Ángel
authors: Á
authors: Concha
references: J Mol Diagn. 2003 Aug;5(3):155-9
references: 12876205
references: Cancer. 2007 May 1;109(9):1721-8
references: 17387718
references: J Clin Oncol. 2008 Oct 20;26(30):4869-74
references: 18794552
references: BMC Cancer. 2007 May 08;7:78
references: 17488519
references: Diagn Cytopathol. 2004 Apr;30(4):251-6
references: 15048960
references: Semin Radiat Oncol. 2002 Oct;12(4):319-28
references: 12382190
references: Pathobiology. 2010;77(1):38-45
references: 20185966
references: J Clin Oncol. 2002 Feb 1;20(3):719-26
references: 11821453
references: Eur J Cancer. 2006 Jul;42(10):1501-6
references: 16762541
references: J Clin Oncol. 2009 Mar 10;27(8):1323-33
references: 19204209
references: J Clin Oncol. 2007 Jan 1;25(1):118-45
references: 17159189
references: Arch Pathol Lab Med. 2007;131(1):18-43
references: 19548375
references: Am J Surg Pathol. 2005 Sep;29(9):1221-7
references: 16096413
references: J Clin Pathol. 2008 Mar;61(3):317-21
references: 17761736
references: Mod Pathol. 2009 Mar;22(3):403-9
references: 19060846
references: Breast Cancer Res Treat. 2005 Sep;93(1):3-11
references: 16184453
references: J Carcinog. 2008;7:8
references: 19008567
references: Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):389-93
references: 18091380
references: J Clin Oncol. 2006 Mar 1;24(7):1037-44
references: 16505422
references: Cancer. 2001 Dec 15;92(12):2965-74
references: 11753973
references: Lancet. 2005 May 14-20;365(9472):1687-717
references: 15894097
references: Mod Pathol. 2002 Jun;15(6):657-65
references: 12065780